Evaluation Of Port Delivery System With Ranibizumab For The Treatment Of Neovascular Age-Related Macular Degeneration

Current treatment of neovascular age-related macular degeneration involves periodic intravitreal injections of anti-VEGF medication, creating a burden to patients and physicians, resulting in nonadherence to recommended dosing schedules. The Port Delivery System with ranibizumab offers a long-term solution that involves implantation of a device into the pars plana and provides continuous release of anti-VEGF medication into the vitreous, thus requiring fewer office visits. The Port Delivery System has demonstrated comparable visual and anatomic outcomes to monthly injections and shows promise in alleviating the patient burden in the treatment of neovascular age-related macular degeneration, making possible better long-term real-world visual outcomes.Tweetable abstractThe Port Delivery System with ranibizumab is an ocular implant that treats neovascular age-related macular degeneration with comparable efficacy to monthly ranibizumab injections and significantly decreased patient burden.